Business Wire

SMITHS-DETECTION

16.4.2024 08:01:30 CEST | Business Wire | Press release

Share
Smiths Detection launches cutting edge X-ray Diffraction scanner

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched the SDX 10060 XDi, a ground-breaking X-ray scanner powered by diffraction technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415145550/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smiths Detection's ground-breaking SDX 10060 XDi, powered by diffraction technology. (Photo: Business Wire)

X-ray Diffraction (XRD) is a powerful inspection technology offering highly accurate material discrimination and substance identification based on an object’s molecular structure. XRD is particularly suited to detecting constantly evolving compounds in powder, liquid or solid forms, such as ‘homemade’ explosives or narcotics, even for materials with similar densities.

Multi-level baggage and material handling operations and express forwarders are under pressure to screen huge volumes quickly and efficiently. The SDX 10060 XDi can transform this process by automating the resolution of potential explosive alarms, in turn improving both security and efficiency.

Due to its exceptional sensitivity, XRD technology can also be very effectively deployed to support customs agencies in screening for a range of contraband items including narcotics, helping to mitigate ever-growing threats to society.

Jerome de Chassey, President of Smiths Detection, commented: “We are immensely excited to announce the launch of the SDX 10060 XDi which marks a new era in security screening. Every minute of every day our threat detection and security screening technology helps to protect people and infrastructure, and this new development highlights our commitment to making the world a safer place. X-ray Diffraction will future-proof operations for a large variety of sectors, and we are proud to play a pivotal role in shaping the landscape of future threat detection.”

The SDX 10060 XDi can integrate seamlessly with existing material and baggage handling systems and is designed to meet ECAC Standard 3.1/3.2 and TSA 7.2 plus future regulations. Certification is underway.

See how XRD will enhance security here: https://youtu.be/CkoCpsrz97I

Jerome de Chassey, President, Richard Thompson, Vice President Marketing and Strategy, and Matthew Clark, Vice President Technology, will be present at Passenger Terminal Expo 2024 on 16 and 17 April, stand A145 in hall 5.1.

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.

For more information visit: http://www.smithsdetection.com/diffraction

About the SDX 10060 XDi:

The Smiths Detection SDX 10060 XDi leverages cutting-edge X-ray Diffraction (XRD) technology to offer unparalleled material discrimination and substance identification capabilities. By generating a unique 'diffraction fingerprint', it can accurately distinguish between substances with similar densities, making it exceptionally effective for identifying homemade explosives and narcotics in various forms. This advanced detection system is especially beneficial for high-volume, high-speed applications such as baggage screening at airports and parcel processing, where it enhances security and operational efficiency.

Discover how the SDX 10060 XDI can elevate your security screening operations here: https://www.smithsdetection.com/products/sdx-10060-xdi/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415145550/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye